University of Montana

ScholarWorks at University of Montana
Graduate Student Theses, Dissertations, &
Professional Papers

Graduate School

2002

Analysis of the bactericidal activity of antiserum raised against
the N-terminal half of an 85-kilodalton outer membrane protein of
Neisseria meningitidis
Leoned G. Gines
The University of Montana

Follow this and additional works at: https://scholarworks.umt.edu/etd

Let us know how access to this document benefits you.
Recommended Citation
Gines, Leoned G., "Analysis of the bactericidal activity of antiserum raised against the N-terminal half of
an 85-kilodalton outer membrane protein of Neisseria meningitidis" (2002). Graduate Student Theses,
Dissertations, & Professional Papers. 7288.
https://scholarworks.umt.edu/etd/7288

This Thesis is brought to you for free and open access by the Graduate School at ScholarWorks at University of
Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an
authorized administrator of ScholarWorks at University of Montana. For more information, please contact
scholarworks@mso.umt.edu.

Maureen and Mike
MANSFIELD LIBRARY

The University of

Montana
Perm ission is granted by the author to reproduce this m aterial in its entirety,
p rovided that this m aterial is used for scholarly purposes and is properly cited in
p u b lish ed w orks and reports.

' *Please check "Yes" or "No" and provide signature

Y es, I grant perm ission
N o, I do not grant perm ission

_________

A uthor's Signature:
Date:

A ny copying for com m ercial purposes or financial gain m ay be undertaken only w ith
the author’s explicit consent.

8/98

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Analysis of the Bactericidal Activity of Antiserum Raised Against the Nterminal Half of an 85-kilodalton Outer Membrane Protein of Neisseria
meningitidis

By Leoned G. Gines
B.S. Washington State University, 1998
Presented in partial fulfillment o f the requirements
for the degree o f
Master of Science
The University of Montana 2002

Approved by:

Tir-

t

/

:

Chairperson

Dean, Graduate School

Date

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

UMI Number: EP38089

All rights reserved
INFORMATION TO ALL USERS
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.

UMT
Din«rtM ion PuWmhing

UMI EP38089
Published by ProQuest LLC (2013). Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against
unauthorized copying under Title 17, United States Code

Proj^^st'
ProQuest LLC.
789 East Eisenhower Parkway
P.O. Box 1346
Ann Arbor, Ml 48106 - 13 46

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Gines, Leoned G., M.S., December 2001

Microbiology

Analysis o f the Bactericidal Activity o f Antiserum Raised Against the N-Terminal Half of an 85kilodalton Outer Membrane Protein of Neisseria meningitidis (54pp.)

Director; Ralph C. Judd

^ ,/

The closely related pathogenic Neisseria species, N. meningitidis and N. gonorrhoeae, infect an
estimated 500,000 and 250 million people annually worldwide, respectively. Development of
effective vaccines to prevent infection has proven difficult. A quadrivalent polysaccharide
vaccine is currently available against N. meningitidis^ however, this vaccine does not confer
protection against all major pathogenic serogroups. Furthermore, because the current
meningococcal vaccine is not based on a protein antigen, it is poor at inducing immunological
memory. There is currently no vaccine available against gonorrhea. Efforts to develop such a
vaccine have been hampered by the lack of an appropriate animal model and tremendous
antigenic- and phase variation exhibited by most major gonococcal outer membrane proteins.
Therefore, attractive vaccine candidates would include less major protein molecules that are
universally and constitutively expressed by pathogenic Neisseria.
A recently discovered 85-kilodalton outer membrane protein (Omp85) of Neisseria appears to
be such a vaccine candidate. Omp85 is universally expressed by Neisseria, and its expression is
highly conserved within species. Furthermore, Omp85 homologues in other pathogenic bacteria
were shown to be capable of inducing protective immunity. The vaccine potential of Omp85 was
evaluated in this project by analyzing the bactericidal activity of rabbit antiserum raised against
the N-terminal 445 amino acids, approximately half entire length, of meningococcal Omp85
(N445mcOmp85). The N-terminal half of Omp85 was the focus of this study because it was
previously shown that the entire Omp85 molecule is difficult to express in E. coli, and
systematically evaluating different fragments of Omp85 will allow for pinpointing of a putative
bactericidal-elicitmg epitope.
Bactericidal assay results indicated that anti- N445mcOmp85 rabbit serum was unable to promote
strong, specific complement-mediated killing of Neisseria. This may be due to the paucity of
Omp85 molecules on the bacterial surface, which would decrease the likelihood of complement
cascade initiation by antigen cross-linking. However, since the function of Omp85 is still
unknown, it is possible that antibodies against Omp85 may disrupt an essential function or
prevent cell adhesion. Thus, further studies to examine the vaccine potential of Omp85 are
warranted.
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Anti-2 (.5) mcOmpSS:

Rabbit serum raised against amino acids 445-798 of
meningococcal Omp85

Anti-N44smcOmp85:

Rabbit serum raised against N44smcOmp85

Anti-PM04:

Rabbit serum raised against the first 178 amino
acids of gonococcal Omp85

C4bp:

C4b-binding protein

CBB:

Coommassie brilliant blue stain

CMP NANA:

Cytidiinemonophospho-N-acetylneuramic acid

dPBS:

Dulbeco’s phosphate buffered saline

ELISA:

Enzyme-linked immunosorbent assay

FMS:

Fulminant meningococcal sepsis

LOS:

Lipooligosaccharide

MAC:

Membrane attack complex

MWM:

Molecular weight marker

N 44sm cO m p 85:

N-terminal 445 amino acids of meningococcal Omp85

NHS:

Normal human serum

NRS:

Normal rabbit serum

Omp85:

85-kilodalton Neisseria outer membrane protein

PID;

Pelvic inflammatory disease

Por:

Neisseria ponn protein

Por A:

Porin A isoform

Por B:

Porin B isoform

pLGl:

pTrcHisB vector containing N445mcOmp85 insert

pTrcHis:

Cloning vector containing trc promotor and poly
histidine tag
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Introduction
Prevention and control of diseases caused by pathogenic Neisseria species. Neisseria
gonorrhoeae and Neisseria meningitidis, have been hampered by lack o f an effective vaccine.
Development of a vaccine against these species has been difficult since a conserved, non
variable, sufficiently immunogenic protein molecule expressed by all strains within a species has
yet to be identified. The goal of this project was to evaluate the vaccine potential of a recently
discovered 85-kilodalton (kDa) Neisseria outer membrane protein (Omp85). Omp85 is
invariantly expressed by all N. gonorrhoeae and N. meningitidis strains studied thus far. In
addition, Omp85 is similar at the amino acid level to bacterial outer membrane proteins known to
elicit protective immunity. Therefore, it is possible that an Omp85-based vaccine would confer
protective immunity against all strains of N. gonorrhoeae and N. meningitidis.

This project primarily focused on the vaccine potential of meningococcal Omp85. Experiments
involving viable meningococci were performed using a non-pathogenic, non-encapsulated strain;
however, since the purpose of this work was to evaluate the vaccine potential of Omp85 against
pathogenic Neisseria, encapsulated N. meningitidis would be used in assays if warranted by
results from the present experiments. Since meningococcal Omp85 is nearly identical to
gonococcal Omp85 at the amino acid level, several strains of N. gonorrhoeae were also used to
evaluate the vaccine potential of meningococcal Omp85. The high identity between
meningococcal- and gonococcal Omp85 would be advantageous to any prospective Omp85-based
vaccine, since such a vaccine could potentially confer protection against both meningococcemia
and gonorrhea.
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1-1. Neisseria meningitidis infection
N. meningitidis is a human pathogen that causes fulminant meningococcal sepsis and
meningococcal meningitis. Fulminant meningococcal sepsis results from proliferation of N.
meningitidis in the blood and release of endotoxins; symptoms include fever, chills, muscle aches,
hemorrhagic skin rash, diffuse intravascular coagulation, and shock. Death may occur within the
first few hours o f disease, resulting in mortality rates of up to 80% (28). Meningococcal
meningitis results when N. meningitidis invades the meninges; symptoms include skin rash, fever,
headache, photophobia, irritability, vomiting, and neck stiffness. Death occurs in up to 5% of
patients due to intracranial pressure (28). Those that recover may suffer from deafness, mental
retardation, or seizures (28).

N. meningitidis occurs naturally in the nose of approximately 10% of the population (28).
However, 90% of these commensal strains are nonpathogenic. Disease occurs when the blood is
accessed by the oropharynx by encapsulated pathogenic strains of N. meningitidis, most of which
belong to one of the following serogroups; A, B, C, W-135, or Y. In industrialized nations,
disease occurrence is 1 to 3 per 100,000; this number increases to 10 to 25 per 100,000 in third
world countries (28). Those most susceptible to disease include young children, immunecompromised individuals, and those subject to abject social conditions. Crowding facilitates
outbreaks of disease, since meningococci are transmitted via direct contact and respiratory
droplets up to a distance of one meter. Consequently, outbreaks are prone to occur in populations
o f military personnel, school children, and jail inmates.

Early administration of penicillin or cephalosporins is effective at treating menmgocccal
infection. However, diagnosis during early stages of infection is difficult since early symptoms
are ambiguous; fever, chills, muscles aches, and vomiting are symptoms common to nonmeningococcal bacterial and viral infections. As a result, treatment may not be initiated until
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later in infection, where the likelihood of a complete recovery is decreased. Emphasis must,
therefore, be placed on disease prevention.

1-2. Neisseria gonorrhoeae infection
Neisseria gonorrhoeae is the causative agent of gonorrhea, a leading cause of urethritis,
cervicitis, and pelvic inflammatory disease (PID) in the United States. Occurrence of this
sexually transmitted disease is known to date back to 2637 BC, when the Chinese emperor Huang
Ti described venereal urethral discharges among his people (23). Symptoms of the disease were
also described by Hippocrates in 400 BC (23). Gonorrhea continues to persist as a prominent
sexually transmitted disease despite effective antibiotic treatments, including penicillin and
tetracycline. This may be partially attributed to the fact that up to 40% of infected men and 80%
o f infected women are asymptomatic for disease (23). Consequently, although effective
treatments are available, many infected individuals do not receive treatment. These
asymptomatic individuals may serve as carriers who spread disease,

N. gonorrhoeae is specifically adapted for survival in the human urogenital tract. Infection is
initiated when the bacterium colonizes the apical side of nonciliated epithelial cells (19). The
organism then travels transcellularly to exit through the basolateral side of the host cell, resulting
in infection of the basement membrane (19). Symptoms of genital gonococcal infection are a
result of damage to the epithelial cells caused by transcellular passage of the bacterium and
inflammation at the infected site. In men, symptoms of uncomplicated genital gonococcal
infection include urethritis, dysuria, and discharge of purulent exudates (23). Local spread of
infection leads to prostatitis, seminal vesiculitis, epididymitis, and inguinal lymphadenitis (23).
Chronic inflammation can lead to blockage of the sperm ducts, resulting in sterility (11). In
women, uncomplicated gonococcal infection primarily affects the columnar epithelium of the
endocervix, resulting in cervicitis. (23). Symptoms include abnormal or increased vaginal
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discharge, abnormal uterine bleeding, dysuria, and frequent urinations (23). Ascending
gonococcal infection causes acute salpingitis and pelvic inflammatory disease (PID) (23).
Chronic scarring of the fallopian tubes may also result, leading to sterility (11), Furthermore,
destruction o f ciliated cells lining the fallopian tube can lead to ectopic pregnancy (11).

Disseminated gonococcal infection (DGI) results from exit of the organism through the
basolateral side of epithelial cells and subsequent entry into the bloodstream. DGI is
characterized by several symptoms, including gonococcal meningitis, gonococcal endocarditis,
infectious arthritis, and dermatitis. The latter is manifested by petechiae, pustules, hemorrhagic
lesions, or ulcerative lesions (23). Non-specific symptoms of DGI include fever, chills, malaise,
liver function abnormalities, and leukocytosis (23). N. gonorrhoeae also infects the
oropharyngeal and ophthalmic regions (11). The latter is most commonly acquired by newborns
through infected birth canals (ophthalmia neonatorum) (11).

1-3. Vaccines currently available against N. meningitidis and N. gonorrhoeae
Development of an effective vaccine against pathogenic Neisseria has proven difficult. A
quadrivalent polysaccharide vaccine is currently available against N. meningitidis serogroups A,
C, W-135, and Y. However, the efficacy of this vaccine is limited by several factors. First,
because the vaccine is not based on a protein antigen, it is poor at inducing immunological
memory. Second, it is not very effective in infants. Last, the vaccine is ineffective against
serogroup B, which causes one-third of all meningococcal infections in the United States and
Europe (28). An effective polysaccharide vaccine against serogroup B will not likely be
developed since its capsular polysaccharide is very similar to neuronal cell adhesion molecule,
thus posing a risk of autoimmunity (28). Furthermore, serogroup B polysaccharide capsule
induces a weak antibody response during natural infection.
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There is currently no vaccine available against N. gonorrhoeae. Efforts to develop such a vaccine
have been hampered by the fact that there is no animal model for gonococcal infection, and most
major outer membrane proteins of N. gonorrhoeae exhibit tremendous antigenic- and phase
variation. Therefore, development of a vaccine against both N. gonorrhoeae and N. meningitidis
would be benefited by less prominent outer membrane protein antigens that are universally and
conservatively expressed by Neisseria, and are capable of inducing protective immunity.
Preliminary evidence suggests that Omp85 may be such an antigen.

1-4. Omp85
Manning et al. discovered Omp85 in the mid-1990’s by screening a genomic library with serum
raised against isolated gonoccocal outer membrane proteins (17). Omp85 was found to contain a
putative signal peptide and a carboxyl-terminal phenylalanine residue, both of which are
characteristic of outer membrane proteins ( 17). Western blot analysis showed that rabbit serum
raised against gonococcal Omp85 cross-reacts with meningococcal whole cell lysates, indicating
that Omp85 is also expressed by N. meningitidis (17). Presence of the Omp85 gene in N.
meningitidis was later confirmed by genome comparison and DNA sequencing (13). The
following preliminary evidence suggests that Omp85 may be used to develop an effective vaccine
against N. meningitidis'. 1) Omp85 is highly similar to outer membrane proteins that have been
shown to induce protective immunity, 2) Omp85 is universally and constitutively expressed in an
invariant manner by all N. meningitidis strains studied to date, and 3) Omp85 is a protein antigen.

Otnp85 is highly similar to outer membrane proteins that induce protective immunity.
A GenBank database search revealed that Omp85 is 61% similar to D-15-Ag of Haemophilus
influenzae and Oma87 of Pasteurella multocida (17). It has been previously shown that D-15-Ag
and Oma87 are capable of inducing protective immunity (8,16,18,26). Loosmore et al.,
demonstrated protective immunity elicited by D-15-Ag when 10 out of 13 rat pups passively
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immunized with anti-D-15 rabbit serum were protected against H. influenzae challenge (16).
Similar findings were reported by Thomas et aL, who demonstrated that preabsorbing a
suspension o f H. influenzae with anti-D-15 antibodies prevented the organism from causing
disease in rats (26). Protective immunity elicited by Oma87 was demonstrated by Ruffolo and
Adler, who showed that anti-Oma87 serum protected mice from P. multocida challenge (24).

Omp85 is universally and constitutively expressed in an invariant manner by N. meningitidis and
N. gonorrhoeae.
Western Blot analysis revealed that Omp85 is expressed by all strains of N. meningitidis and N.
gonorrhoeae studied to date (13). DNA sequence analysis showed that Omp85 is identical in all
intraspecies strains (13). Interspecies homology is also high; at the amino acid level,
meningococcal- and gonococcal Omp85 are 95% identical and 98% similar (17).
Meningococcal- and gonococcal Omp85 are also nearly identical at the nucleic acid level, with
only one region of variation occurring between base pairs 720 and 752.

Omp85 is a protein antigen.
Shortcomings of the current capsular polysaccharide meningococcal vaccine are outlined above.
Since Omp85 is a protein antigen, it is not subject to the limitations of a polysaccharide antigen.
Thus, an Omp85-based vaccine may potentially induce immunological memory, confer protection
upon infants, and have effectiveness against N. meningitidis serogroup B.

The function of Omp85 is currently unknown. However, the following functions have been
hypothesized:
1) Omp85 may be involved in mucosal colonization by Neisseria. All species of Neisseria
colonize mucosal surfaces (17). Since Omp85 is expressed by all pathogenic and non-pathogenic
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Neisseria species studied thus far, it is possible that Omp85 may play a role in mucosal
colonization.
2) Omp85 may be involved in protein transport. GenBank database search revealed 35%
similarity between Omp85 and a chloroplast outer membrane protein (IAP75) (17). IAP75
belongs to a complex of outer membrane proteins that function in polypeptide transport (17).
Thus, Omp85 may play a similar role in Neisseria.
3) Omp85 may be involved in signal transduction. GenBank database search revealed 33%
identity between Omp85 and Photorhabdus luminescens outer membrane antigen (Oma)
(GenBank accession No AJ236920, Chatonnet-Marton, et al., unpublished data). P. luminescens
Oma is located in a genomic region that promotes pleiotropy in response to various
environmental conditions (9). Therefore, it is possible that Omp85 may be involved in signal
transduction.

1-5. Research Goal, Hypothesis, and Specific Aims
The long-term goal of this work is to evaluate the vaccine potential of meningococcal Omp85. In
this project, the ability of Omp85 to induce the generation of bactericidal antibodies was
investigated.
Hypothesis
The hypothesis tested was that rabbit antiserum generated against the first 445 amino acids of
meningococcal Omp85 (N44smcOmp85) specifically triggers complement-mediated killing of N.
meningitidis and N. gonorrhoeae. The N-terminal half of Omp85 was the focus of this s tudy
because it was previously shown that the entire Omp85 protein is difficult to express in E. coli,
and systematically evaluating different fragments of Omp85 will allow for pinpointing of a
putative bactericidal-elicitmg epitope.
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To test the hypothesis, the following Specific Aims were investigated:
1) DNA encoding for N4450mp85 was cloned into a hyperexpression vector.
2) Recombinant N^^^OmpSS was hyperexpressed in E. coli, then purified by affinity
chromatography.
3) Rabbit antiserum was generated against purified recombinant N^^^OmpSS.
4) Anti- N4450mp85 rabbit serum was used in bactericidal assays against
N. meningitidis and N. gonorrhoeae.
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Materials and Methods
2-1. Bacterial Strains
Strain

Source

N. gonorrhoeae FA 19

Dr. P. Fred Sparling, University of North
Carolina, Chapel Hill, NC
Dr. Keith Joiner, NIH, Bathesda, MD

N. gonorrhoeae FA638
N. gonorrhoeae JSl
N. gonorrhoeae MS 11 LOS A
N. meningitidis 8543
N. meningitidis HH

Dr. John Swanson, Rocky Mountain
Laboratories, NIAID, NIH, Hamilton, MT
Dr. John Swanson, Rocky Mountain
Laboratories, NIAID, NIH, Hamilton, MT
Dr. Richard Rest, Hahnemann School of
Medicine, Philadelphia, PA
Dr. Zell McGee, University of Utah, Salt Lake
City, UT

2-2. DNA Isolation
N. meningitidis HH was grown in 3 ml gonococcal clear typing broth (GC broth, 37°C with 5%
COi) to an ODeoonm » 1.0 .

This culture, 0.25 ml, was then used to inoculate 5 ml GC broth.

This was grown to an ODeoonm = 0.4 - 0.6, then centrifuged at 3000 rpm for 10 mm. The resulting
pellet was resuspended in 567 pi TioE, (lOmM Tris, ImM EDTA), then treated with 30 pi of
10% SDS, 6 pi proteinase K (20 mg/ml), and 1 pi Rnase A (10 mg/ml). This was mixed and
incubated at 37 °C for 1 hr. Phenol extraction was then performed (4), and DNA was
resuspended in 100 pi T,oE,.
2-3. SDS-PAGE and Western blotting
Discontinuous sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was
performed essentially as described by Laemmli (15). The protocol for Neisseria whole cell
lysates was described by Judd (12). Separated proteins were transferred to polyvinylidine
diflouride membranes using a Bio-Rad Trans Blot Cell. The transfer was performed in degassed
20 mM sodium phosphate buffer, pH 8.0, for 16 hr at 450 mA. The membrane was blocked for 1
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hr in Dulbeco’s phosphate buffered saline (dPBS) containing 2% skim milk prior to an overnight
incubation in diluted primary antibody (in dPBS). The membrane was then incubated for 1 hr in
protein A-horseradish peroxidase (1:2500 dilution dPBS). Blots were developed in 4-chloro-i naphthol and hydrogen peroxide buffered in methanol.
2-4. Genetic fusion of n44smcOmp85 to poly-histidine tag
A. Polymerase Chain Reaction (PCR)
Primers were designed to amplify bases 76-1396 of meningococcal Omp85, 25 nucleotides
downstream of the signal peptide cleavage site (Figure 1). Primer designations and sequences
were as follows:
5’ mOmp85 pTrcHis TOPO: 5’ CAAGACATCCGTGTCGAA 3’
3’ GC-1(.5) Omp85: 5’ GTTAGCTTCGCGAGGC 3’
Plasmid DNA containing Omp85 from N. meningitidis HH ( 17) was used as the template. Prior
to PCR amplification, the template was linearized by treatment with the PstI restriction enzyme.
Reactions were performed using AccuTaq^*^ LA DNA Polymerase (Sigma-AIdrich, D8045) and
Perkin-Elmer Cetus Thermocycler Model 480. The following parameters were used:
1. 95° C

1 minute

2. 95° C
62° C
72° C

1 minute
30 seconds
1 minute

3. 72° C

7 minutes

^

_J

25 cycles

Restriction enzyme analysis using ^cc7 and H in d i was performed on the amplified DNA to
verify its identity (see Figure I for map of restriction sites).
B. Plasmid Construction (see Figure I fo r schematic diagram)
The pTrcHisTOPO TA Cloning Kit (Invitrogen, K4410-01) was used to insert PCR-amplified
fj^^pncOmp85 into the pTrcHisTOPO plasmid. All reactions were performed according to
manufacturer’s specifications. Transformation of the recombinant plasmid into TOP 10 One
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Shot® E. coli cells was performed according to manufacturer’s specifications then plated onto LB
agar containing 50 pg/ml ampicillin and 0.2% glucose. Plasmid DNA was isolated from
transformants using a QIAprep Spin Plasmid Kit (Qiagen, 27104), then analyzed by restriction
digest to check for presence and orientation of the insert. Two sets of double digests using
BamHI/EcoRl und Aval/EcoRI were used for the analysis (see Figure 1).
C. Subcloning is445mcOmp85 into pTrcHisB
To obtain optimal expression of the fusion protein, M4smcOmp85 was subcloned out of
pTrcHisTOPO and into the pTrcHisB plasmid using the Xpress™ System (Invitrogen, V36020).
Plasmid DNA consisting of pTrcHisTOPO plus N44}fncOmp85 was isolated from transformed
TOP 10 One Shot® £. coli cells using a Midi Plasmid Purification Kit (Qiagen, 12143). BaniHI
and EcoRl 'Next then used to excise m45fncOmp85 from pTrcHisTOPO. The resulting fragments
were electrophoresed on a 1% agarose gel, and the excised insert was gel purified using a
QIAquick Gel Extraction Kit (Qiagen, 28704). The excised t444snicOmp85 was then ligated into
the BamHI and EcoRl sites of pTrcHisB using T4 DNA Ligase (New England Biolabs, Inc.). The
resulting plasmid was designated pLGl (see Figure 1 for schematic diagram). Prior to ligation,
pTrcHisB was treated with calf intestine alkaline phosphatase (Boehringer Mannheim) to prevent
self-ligation. Plasmid pLGl was transformed into E. coli DH5a cells (Gibco BRL) according to
manufacturer’s specifications. Transformants were screened for presence and orientation of the
insert using PCR- and restriction enzyme analysis. The latter involved a single digest using AccI
and a double digest using HindllHNhel.
2-5. Expression of fusion protein
The fusion protein was expressed according to the protocol provided by Invitrogen. Briefly,
ToplO cells containing pLGl were grown overnight in 1 ml LB broth containing 50 pg/ml
ampicillin and 0.2% glucose. From the overnight culture, 0.2 ml was used to inoculate 10 ml LB
broth containing 50 pg/ml ampicillin. This was grown to an ODüoonm of approximately 0.6, at
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which point expression was induced by adding IPTG to a final concentration of 1 mM. Induction
was allowed to proceed for 4 hours. Aliquots of cells, 1 ml, were then collected and centrifuged.
The resulting pellets were solubalized in 100 pi SDS-PAGE sample buffer. Western blot was
then performed as described by Judd (12) to verify that the pelleted cells expressed the fusion
protein. Rabbit antiserum, previously generated against the first 178 amino acids of gonococcal
Omp85 (17), was used as the primary antibody (1:500 dilution in dPBS). Protein A-horseradish
peroxidase was used to detect the primary antibody (1:2500 dilution in dPBS).
2-6. Purification of fusion protein
Recombinant N44snacOmp85 was purified using pTrcHis Expression and Purification Kit
(Invitrogen, K860-01). A 50 ml culture of induced cells was harvested by centrifuging at 3000
rpm for 10 min. Cells were resuspended in 1/10 the culture volume of ice-cold 10 mM Trisacetate containing 0.75 M sucrose, pH 7.8. Egg white lysozyme was added to an approximate
final concentration of O.I mg/ml, then the cells were incubated on ice for 2 min. Cells were
handled very gently at this point to prevent premature release of the fusion protein. Two volumes
o f ice-cold 1.5 mM EDTA were slowly added over a period of 10 min, while applying gentle
agitation. The cells were then centrifuged at 2500 rpm for 10 min, then resuspended in 1/5 the
culture volume of guanidinium lysis buffer. Cells were sonicated on ice (20 second bursts, 10
second rests) for a total of 5 min. The sonicated material was then centrifuged at 13,000 rpm for
15 min to separate out insoluble debris. The supernatant, which contained the fusion protein, was
applied in batch mode to a ProBond™ nickel column (Invitrogen). Subsequent binding and wash
steps were performed according to manufacturer’s specifications using low speed centrifugation.
The fusion protein was then eluted off the column in I ml fractions. All fractions were analyzed
by SDS-PAGE and Coomassie Brilliant Blue staining as described previously (27). Fractions
containing purest N44smcOmp85 were pooled and dialyzed against water. Protein concentration
was approximated using bovine serum albumin standards.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

13

2-7. Generation of ant:-N44smcOmp85 rabbit serum
Polyclonal rabbit serum against recombinant N445mcOmp85 was generated as described by
Porcella (21). Prior to immunization, serum was collected from the rabbit for use as a control.
Primary immunization, consisting of 0.5 mg purified N44smcOmp85 (in dPBS) and 0.5 ml
Freund’s complete adjuvant, was administered subcutaneously at four sites into a New Zealand
White rabbit (Western Oregon Rabbit Company). Two weeks later, secondary immunization,
consisting of 0.5 mg purified N44smcOmp85 (in dPBS) and 0.5 ml Freund’s incomplete adjuvant,
was administered subcutaneously at four sites. Intravenous boosts, consisting of 1 mg purified
N445mcOmp85 in dPBS, were then administered weekly over a period of two months. Antibody
titer was determined using Western blot strips containing solubalized N. gonorrheae MSI 1
LOSA.
2-8. Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA using N. gonorrhoeae MS 11 LOS A as plating antigen was performed to determine
antibody titer and to evaluate surface reactivity of anti- N445mcOmp85 antibody. N. gonorrhoeae
MSI 1 LOS A was grown in GC broth to an ODôoonm = 0.68, which corresponds to approximately
5x10^ cfti/ml. Cells were pelleted, then resuspended in an equal volulme of PBS. To fix the
cells, gluteraldehyde was added to a final concentration of 0,5%, then incubated overnight at 4°C.
Cells were then washed three times in PBS. Plating was performed by dispensing 100 pi of
5x10^ cfu/ml fixed cells into an Immulon 96-well plate. The plate was centrifuged at 3000 rpm
for 15 min, then the supernatant was aspirated off. Cells were air dried onto the plate by
incubating at 4°C overnight. Wells were blocked by adding 200 pi of 1% BSA in PBS (BSAPBS), then incubating at room temperature for 2 hr with gentle agitation. Wells were washed
three times in BSA-PBS. Primary antibody was diluted in PBS-BSA, then 100 pi was added to
each well. This was incubated overnight at 4°C, followed by three washes with BSA-PBS. Antirabbit IgG alkaline phosphatase conjugate (Sigma, A-3687) was diluted 1:5000 in BSA-PBS, then
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100 |u,l was added per well. This was incubated for 1 hr at 4°C, followed by three washes with
BSA-PBS. The substrate was prepared by adding 1 tablet of p-nitrophenyl phosphate (NPP) in 10
ml o f IM diethanolamine buffer. The prepared substrate, 100 pi, was then added to each well.
Reaction was allowed to proceed for 20 min before measuring optical density of the wells at
wavelength 405 nm using a Vmax ELISA plate reader.
2-9. Bactericidal Assay
The bactericidal assay performed was a modified version of the assay described by Cadieux (6).
Serum was incubated at 56 °C for 45 min to eliminate intrinsic complement proteins, then filter
sterilized by passage through a Millex-GP 0.22 pm filter (Fisher, SLOP R25 LS) that was
previously blocked with 1% BSA in PBS. Two-fold serial dilutions of the serum were then
prepared (1:4 to 1:1024) in Hanks’ balanced salt solution containing 1% (w/v) casein hydrolysate
(HBSS-cas). Next, 70 pi of each serum dilution was dispensed into separate wells of a 96-well
microtiter plate. Fresh cultures of transparent non-piliated N. gonorrhoeae, adjusted to a density
o f 8x10^ cells/ml in 31 pi HBSS-cas, were then added to each well. This was incubated for 15
min at 37 °C with 5% CO 2 . Each well then received 12.5 pi of human complement (Sigma, S1764) that was preabsorbed with gluteraldehyde-fixed N. gonorrhoeae. This was incubated for
45 min at 37 °C with 5% CO2 , after which 100 pi from each well was plated onto a GC plate.
Plates were incubated overnight, then bactericidal endpoint was calculated.
2-10. Biotinylation and Immunoprécipitation Combination Assay
A biotinylation assay was performed using ECL protein biotinylation module (Amersham
Pharmacia, RPN 2202). N. gonorhoeae MSI 1 LOS A was grown in GC broth to a density of
-5x10^ cfu/ml (OD6oonm=0.68). Cells were then washed three times in ice-cold dPBS. After the
final wash, cells were resuspended in two-thirds the culture volume of ice-cold 40mM
bicarbonate buffer. Biotinylation reagent was added (40 pi per ml of cells), at which point the
cells were incubated for precisely 30 min at 4°C with gentle agitation. Cells were then washed
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three times in ice-cold dPBS. After the final wash, the pellet was resuspended in an equal volume
o f lysis buffer (250 mM NaCl; 25 mM Tris-HCl, pH 7.5; 5 mM EDTA, pH 8.0; 1% Triton-X
100), then incubated at 4°C for 45 min with gentle agitation. The lysate was then centrifuged at
13,000 rpm for 10 min. To 100 pi of the supernatant containing soluble biotinylated outer
membrane proteins was added 50 mg prewashed protein A-sepharose beads (Sigma, P-3391) and
100 pi anti-N44snficOmp85 rabbit serum that was preabsorbed with DH5a/pTrcHisB lysate. This
mixture was incubated for 1 hr at 4 °C with gentle agitation. The beads were then washed three
times in 1 ml dPBS. After the final wash, beads were solubalized in 100 pi of Ix solubilizing
solution. The beads were subsequently collected by centrifugation. To visualize proteins bound
to the beads. Western blot was performed on the supernatant as described previously (12). The
membrane was blocked in 5% ECL blocking agent in PBS-T for 1 hr, followed by three washes
in PBS-T. Streptavidin-horseradish peroxidase conjugate (1:1500 dilution in PBS-T) was then
added to the membrane, and incubated at 4°C for 1 hr with gentle agitation. The membrane was
then washed three times in PBS-T. To detect biotinylated proteins, equal volumes of ECL
detections solutions 1 & 2 were mixed, then applied to the protein side of the membrane. This
was incubated for precisely 1 min at room temperature without agitation. Excess detection
reagent was then decanted, and the membrane was wrapped in Saran wrap. In a darkroom, the
wrapped membrane was placed in an X-ray film cassette together with Hyperfilm MP
Autoradiography Film (Amsersham Pharmacia, RPN 1677K), with the protein side of the
membrane facing the film. The film was exposed for 90 sec, then developed immediately using
GBX Developer (Sigma, P-7042).
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2-11. Immunoprécipitation Assay
N. gonorrhoeae MS 11 LOS A was grown in GC broth to a density of -2x1 O'* cfu/ml
(OD6oonm=0.34). Cclls wctc then washed three times in ice-cold dPBS. To prevent cell lysis,
cells were resuspended each time using gentle pipetting. After the final wash, cells were
resuspended in one-fifth the culture volume of dPBS. Washed cells, 2 ml, were mixed with 1 ml
anti-N445mcOmp85 rabbit serum that was preabsorbed with DH5a/pTrcHisB lysate. This was
incubated for 1 hr at 4°C with gentle agitation. Cells were then gently washed twice with icecold dPBS to eliminate unbound antibodies. After the final wash, cells were resuspended in 3 ml
of ice-cold dPBS. Prewashed protein A-sepharose beads (Sigma, P-3391), 150 mg, were then
added to the cells and incubated for 1 hr at 4°C. The beads were then centrifuged at 1000 rpm for
2 min, and the supernatant removed. To release antigens, the beads were vigorously resuspended
in 3 ml o f a mild lysis buffer [250 mM NaCl; 25 mM Tris-HCl, pH 7.5; 5 mM EDTA, pH 8.0;
1% (v/v) Triton-X 100], and incubated at 4°C for 30 min with gentle agitation. The beads were
then centrifuged at 1000 rpm for 2 min, and washed in 3 ml dPBS. This was repeated for a total
o f three washes. The beads were then solubalized in 150 pi of 2x solubilizing solution, after
which the beads were spun down and the supernatant was saved. The supernatant was loaded
onto an SDS-PAGE gel, then analyzed via Western blot.
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Results
3-1. Genetic Fusion of N445mcOnip85 to Poly-Histidine Tag
A. Cloning N445mcOmp85 into pTrcHis-TOPO
N44$rrtcOmp85 was inserted into a hyperexpression vector containing a poly-histidme tag to allow
for purification and characterization of the expressed protein. The pTrcHis-TOPO vector used
allowed for efficient insertion of PCR products. Nucleotides 76-1396 of meningococcal Omp85
were PCR-ampIified and inserted into pTrcHis-TOPO. The vector sequence immediately
flanking the 5’ end of the insert was similar to nucleotides 64-75 of meningococcal Omp85 at the
amino acid level (Figure 2). Thus, in total, nucleotides 64-1396 of meningococcal Omp85 were
essentially cloned into pTrcHis-TOPO. The signal sequence of meningococcal OmpSS was
omitted in this construct to prevent toxic accumulations of the expressed protein at the surface of
transformed cells. Expression of the vector’s ampicillin resistance gene occurs only when an
insert is present. Thus, all colonies that appeared on an ampicillin plate following cloning and
transformation reactions were considered to have taken up a vector containing an insert. To
confirm correct orientation of the insert, plasmid DNA from several colonies was analyzed using
restriction enzymes AccI, BamHI, and EcoRl (Figure 1).
B. Subcloning \44smcOmp85 intopTrcHisB
Expression levels of N44sOmp85 in the pTrcHis-TOPO vector were not as high as expected .
Therefore, N44sOmp85 was subcloned out of pTrcHis-TOPO and into pTrcHisB, a similar vector
that also contains the poly-histidine tag. The insert was excised from pTrcHis-TOPO using
EcoRJ

BamHI, then ligated into pTrcHisB using corresponding restriction sites (Figure 1).

The resulting plasmid was designated pLGl (Figure 3). Following cloning and transformation
reactions, several colonies were screened using PCR analysis to confirm presence of the insert.
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Plasmids from colonies that contained the insert were subsequently analyzed using restriction
enzymes AccI, Hindlll, and Nhel to confirm correct orientation (Figure 1).
3-2. Expression and Purification of Recombinant N445mcOmp85
Expression of recombinant N44snicOmp85 in transformed TOP 10 One Shot® E. coli cells was
induced with IPTG. To determine optimal induction time, 1 ml samples of transformed cells
were collected at 2 hr, 4 hr, and 16 hr post induction. Each sample was separated on a 12.5%
SDS-PAGE gel, then analyzed by CBB staining. An induced protein of approximately 55 kDa,
which is the expected molecular mass of recombinant N44smcOmp85, was present in all samples.
Optimal expression of the fusion protein occurred after a 16 hr induction (Figure 4). To confirm
identity of the induced protein, each sample of transformed cells was analyzed via Western blot.
Antibody previously generated against the first 178 amino acids of gonococcal Omp85 (antiPM 04) (17) was used as a probe. Anti-PM04 reacted with a -55 kDa protein in all samples
containing pLGl (Figure 5), indicating that the induced protein was indeed recombinant
N44smcOmp85. A ~55 kDa band was visible in the lane containing uninduced N445mcOmp85
clone; however, this band was not observed in the CBB-stained SDS-PAGE gel of the uninduced
clone. Since Western blot is much more sensitive than CBB staining at detecting proteins, these
results may indicate expression of small amounts of the recombinant protein prior to IPTG
induction, which is not uncommon. Purification of recombinant N44smcOmp85 was performed
using affinity chromatography; induced transformants were disrupted by sonication, then applied
to a nickel column. The identity of the eluted protein was again confirmed by CBB staining of a
12.5% SDS-PAGE gel, which revealed the presence of a -55 kDa protein (Figure 6). Identity of
the eluted protein was also confirmed by Western blotting. Antibody against the Xpress™
epitope o f the recombinant protein (Identified in Figure 3) was used to probe the blot. In
agreement with the CBB stain, the probe also detected a protein of approximately 55 kDa
(Figure 7).
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Figure 1. Construction of pLGl. Nucleotides 76-1396 (indicated in parentheses) of N.
meningitidis HH Omp85 (N445mcOmp85) were PCR-amplified using the following primer pair,
which was designed to omit the Omp85 signal peptide: 5’ mOmp85 pTreHis TOPO and 3’ GC1(.5) Omp85. The PCR product (designated as a 1320 bp insert) was then ligated into pTrcHisTOPO. N445incOmp85 was subsequently excised out of pTrcHis-TOPO, gel-purified, and then
inserted into the pTrcHisB multiple cloning site (MCS) using BamHI and EcoRI restriction sites.
The resulting plasmid, termed pLG l, was constructed so that N44snicOmp85 was directly adjacent
to an enterokinase cleavage site (EK) and a poly-histidine tag [(Hisle], which allowed for affinity
purification of the recombinant protein product. Plasmid LGl contained several restriction sites
(position, relative to recombinant protein start codon, is indicated in parentheses) that were used
to confirm presence and orientation of the insert.
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Nucleotides 64-75 o f mcOmp85
asp \ p h e i thr \ He
G AC TTC i c d ATC

G A T p C A ÀCÇ CTT
,asp \ pro IM rJ leu

Nucleotides 76-1396 o f mcOmpSS

pTrcHis-TOPO-N445incOmp85

Figure 2. Cloning o f nucleotides 64-1396 of N. meningitidis HH Omp85 into pTrcHis-TOPO.
The inserted PCR producted (indicated by gray shading) was comprised of nucleotides 761396 of meningococcal Omp85. Vector sequence immediately flanking the N-terminal end of
the inserted PCR product was similar, at the amino acid level, to nucleotides 64-75 of
meningococcal Omp85; two of the four amino acid residues were conserved (indicated by
dashed boxes) between the two sequences. Thus, nucleotides 64-1396 of meningococcal
Omp85 were essentially cloned into pTrcHisB.
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BamH

EcoRI

G GAT CCA ACC CTT CAA GAC ATC CGT GTC GAA ... GTT AGC TTC GCG AGG CAG

Multiple
CloningSite
(His)

Amp*^

pLGl

C o lE l
Figure 3. Map o f pLGl. Nucleotides 64-1396 of meningococcal Omp85 were inserted into
the multiple cloning site of pTrcHisB using BamHI oxié ÆcoÆ/restriction sites. Adjacent to
the insertion site were a poly-histidine tag (to allow for affinity purification of the expressed
recombinant protein), and an Xpress™ epitope (to allow for detection of the recombinant
protein using anti-Xpress antibody). Other plasmid features include an ampicillin resistance
gene to allow for screening of transformants; ColEl -derived origin; lac' gene encoding for a
lac repressor, which regulates the promoter; and trc promoter region for high-level inducible
expression in E. coli.
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3-3. Generation of Anti-N445mcOmp85 Rabbit Serum
Three months following primary immunization, anti-N445mcOmp85 serum was at a titer of at least
1:32,000, as determined by Western blot strips containing whole cell lysates of TV. gonorrhoeae
MSI 1 LOS A. To ensure that the rabbit was not previously exposed to an environmental Omp85expressing bacterial strain, serum was collected from the animal prior to the first immunization
(normal rabbit serum). Western blot and ELISA analysis showed that normal rabbit serum did
not react with the immunogen (Figures 8 & 9), suggesting no previous exposure to any Omp85like protein. Reactivity of anti-N44;mcOmp85 serum against Omp85 was confirmed by Western
blot analysis, in which the serum was used to probe the immunogen and various strains of
Neisseria (Figure 10). When reacted against the immunogen and the E. coli clone expressing
N44sOmp85, anti-N44smcOmp85 serum detected a protein of approximately 55 kDa; when reacted
against a panel of Neisseria strains, anti-N44smcOmp85 serum detected a protein of approximately
85 kDa. Since the expected molecular weights of N44;nicOmp85 and Omp85 are 55 kDa and 85
kDa, respectively, these results suggest that antibody response against N445mcOmp85 was due to
exposure to the immunogen.
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Figure 4. CBB-stained polyacrylamide gel illustrating induced expression of recombinant
N445mcOmp85 in DH5a. Lane 1 contains uninduced clone, lane 2 contains clone following a 2
hr induction, lane 3 contains clone following a 4 hr induction, and lane 4 contains clone
following a 16 hr induction. Recombinant N445mcOmp85, which has an expected molecular
mass of 55 kDa, is indicated with an arrow.
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Figure 5. Western blot illustrating expression of recombinant N443mcOmp85 in E. coli DH5a.
Lane 1, GIBCO Benchmark prestained molecular weight marker (MWM), expressed in
kilodaltons; lane 2, N44smcOmp85 clone induced for 16 hr; lane 3, N445mcOmp85 clone
induced for 4 hr; lane 4, N445mcOmp85 clone induced for 2 hr; lane 5, uninduced
N445mcOmp85 clone; lane 6, DH5a. Blot was probed with antibody against the first 173
amino acids of gonococcal Omp85, Bound antibody was detected using horseradish
peroxidase-protein A conjugate. Recombinant N44smcOmp85, which has an expected
molecular weight of 55 kDa. is indicated with an arrow.
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Figure 6 Coommassie brilliant blue-stained polyacrylamide gel illustrating purified
recombinant N445mcOmp85, which has an expected molecular weight of 55 kDa. Lane 1,
GIBCO Benchmark prestained molecular weight marker (MWM), expressed in kilodaltons;
lane 2, pure recombinant N445mcOmp85; lane 3, induced N44;mcOmp85 clone; lane 4,
uninduced N445mcOmp85 clone; lane E. coli DH5a
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Figure 7. Western blot confirming identity of purified recombinant N44;mcOmp85, which has
an expected molecular weight of 55 kDa. Blot was probed with antibody against the Xpress™
epitope of the recombinant protein (see figure 3 for map). Bound antibody was detected using
anti-mouse IgG conjugated to horseradish peroxidase. Lane 1, GIBCO Benchmark prestained
molecular weight marker (MWM), expressed in kilodaltons; lane 2, purified recombinant
N445mcOmp85; lane 3, recombinant N44smcOmp85-expressing clone; lane 4, E. coli DH5a.
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Figure 8. Western blot depicting lack of reactivity of normal rabbit serum against various
Omp85-expressing isolates. Lane 1, GIBCO Benchmark prestained molecular weight marker
(MWM), expressed in kilodaltons; lane 2, pure recombinant N445mcOmp85; lane 3,
N445mcOmp85-expressing clone; lane 4, N. meningitidis 8543 whole cell lysate; lane 5, N.
gonorrhoeae MSI 1 LOS A whole cell lysate; E. coli DHSa.
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Figure 9. ELISA depicting reactivity of normal rabbit serum and anti-N445iïicOmp85 serum
against Omp85. Purified recombinant N44gmcOmp85 was used as the plating antigen. Optical
density of the wells was measured 25 min after addition of substrate.
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Figure 10. Western blot demonstrating reactivity of anti-N445mcOmp85 serum against various
Omp85-expressing isolates. Lane 1, GIBCO Benchmark prestained molecular weight marker
(MWM), expressed in kilodaltons; lane 2, purified recombinant N445iTicOmp85; lane 3, lysate
o f N445mcOmp85-expressing clone; lane 4, N. meningitidis 8543 whole cell lysate; lane 5, N.
gonorrhoeae MSI 1 LOS A whole cell lysate; lane 6, E. coli DH5a lysate. Recombinant
NM.icmcOmn85 has an exnected molecular mass of 55 kDa.
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3-4. Bactericidal Assay
The bactericidal assay was performed as described by Cadieux (6), with modifications. Human
complement was preabsorbed with gluteraldehyde-fixed N. gonorrhoeae prior to inclusion into
killing mixtures. This was done to remove proteins that may mediate non-specific, antibodyindependent killing. One nonpathogenic, unencapsulated strain of N. meningitidis and four
strains o f N. gonorrhoeae were assayed for their susceptibility to a-N4 4 5 mcOmp85-mediated
complement killing. Two-fold serial dilutions of a-N445mcOmp85 serum were prepared to allow
for determination of killing titer, which was defined as the reciprocal of the last serum dilution
that produced no bacterial growth. Results are shown in Tables 1-5. Table 1 shows bactericidal
assay results for N. meningitidis 8542. This strain was comparatively sensitive to complement
killing, as 10% complement prevented growth in all dilutions of both a-N445mcOmp85 and normal
rabbit serum; killing mixtures in which complement was not added back resulted in growth of
large numbers of colonies in all serum dilutions. Therefore, to allow for calculation of antibodymediated killing titer, complement concentration was reduced to 5%. Anti-N44smcOmp85 serum
produced a killing titer of approximately 8; however, no significant difference in killing titer was
observed between anti-N44smcOmp85 and normal rabbit serum. Table 2 shows bactericidal assay
results for N. gonorrhoeae MS 11 LOS A. Large numbers of colonies grew in all serum
dilutions, indicating that this strain was resistant to serum killing. Bactericidal assay results for
N. gonorrhoeae FA 19 are shown in Table 3. None of the serum dilutions hindered growth,
indicating that this strain was also resistant to serum killing. Table 4 shows bactericidal assay
results for N. gonorrhoeae J S l . Anti-N445mcOmp85 serum produced a killing titer of
approximately 2; however, no significant difference in killing titer was observed between antiN445rncOmp85 and normal rabbit serum. Table 5 shows bactericidal assay results for N.
gonorrhoae FA638. Compared to other test strains, N. gonorrhoeae FA638 was especially
sensitive to rabbit serum-mediated complement killing, as indicated by the relatively high killing
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titer for both anti-N445mcOmp85 and normal rabbit serum; serum dilutions in which complement
was not added back did not seem to inhibit bacterial growth. An approximately two-fold
difference in killing titer was observed between anti-N44smcOmp85 and normal rabbit serum.
This suggests that N. gonorrhoeae FA638 is slightly susceptible to complement killing that is
mediated by antibody against the first 445 amino acids of Omp85.
3-5. Biotinylation and Immunoprécipitation Combination Assay
To test for surface exposure of Omp85, an immunoprécipitation assay was performed on
gonococcal whole cells using anti-N445mcOmp85 rabbit serum. Omp85 comprises only a small
percentage o f total Neisseria outer membrane proteins, as indicated by SDS-PAGE and CBB
staining o f whole cell lysates. Therefore, to amplify any potential signal produced by antibody
binding to Omp85, gonococcal whole cells were biotin-labeled prior to immunoprécipitation.
ECL detection reagents failed to detect any biotinylated proteins immunoprecipitated by antiN445mcOmp85 rabbit serum. Lysate of biotinylated whole cells was detected, indicating that the
biotinylation and detection procedure was not flawed. To test for the possibility that biotin
labeling blocked binding sites for anti-N44snicOmp85, the antiserum was used to probe
biotinylated and unlabeled whole cells via Western blot and ELISA. The Western blot revealed
that anti-]vj445mcOmp85 detected an -85 kDa protein fi-om unlabeled cells; anti-N44smcOmp85
failed to detect Omp85 from biotinylated cells (Figure 11). Likewise, the ELISA showed greater
reactivity of anti-N44stncOmp85 against unlabeled whole cells, as compared to reactivity against
biotinylated cells. Also tested were antibody against the first 178 amino acids of gonococcal
Omp85 (anti-PM 04) and antibody against amino acids 445-798 of meningococcal Omp85 (anti2(.5)mcOmp85). Both Anti-PM04 and anti-2(.5)mcOmp85 exhibited decreased reactivity
against biotinylated gonococcal whole cells, as determined by Western blot and ELISA
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aiv445»ncOmp85
+10% C’
1
1
1
1
1
1
1
1
1
1

2
4
8
16
32
64
128
256
512
1024

0
0
0
1
0
0
17
1
0
0

Normal
rabbit
serum
+10% C’
0
0
1
0
0
0
0
0
0
1

aN44smcOmp85
+5% C’

0
0
6
40
100
100
100
75
75
250

Normal
rabbit
serum +
5% C’
1
2
11
100
150
150
200
150
150
150

a^4j5mcOmp8
5 without C’

250
250
250
250
200
200
200
150
150
200

Table 1: Bactericidal assay to evaluate complement-mediated killing of N. meningitidis 8542
induced by anti-N445iricOmp85. Number of colonies counted on each plate is indicated.

1
1
1
1
1
1
1
1
1
1

2
4
8
16
32
64
128
256
512
1024

aN44smcOmp85
+10% C’
200
225
225
225
200
225
225
200
225
225

Normal rabbit
serum +10% C’
225
200
150
125
150
150
150
175
175
200

aN445mcOmp85
without C’
150
150
175
175
125
125
125
50
35
22

Table 2: Bactericidal assay to evaluate complement-mediated killing of N. gonorrhoeae MSI 1
LOS A induced by aN445mcOmp85. Number of colonies counted on each plate is indicated.
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1
1
1
1
1
1
1
1
1
1

2
4
8
16
32
64
128
256
512
1024

aN44smcOmp85
+10% C’
200
200
200
200
200
200
200
200
200
200

Normal rabbit
serum +10% C’
200
200
200
200
200
200
200
200
200
200

aN44smcOmp85
without C’
200
200
200
200
200
200
200
200
200
200

Table 3: Bactericidal assay to evaluate complement-mediated killing of N. gonorrhoeae FA19
induced by (%N445mcOmp85. Number of colonies counted on each plate is indicated.

1
1
1
1
1
1
1
1
1
1

2
4
8
16
32
64
128
256
512
1024

aN44snicOmp85
+10% C’
2
50
50
150
200
200
200
200
270
270

Normal rabbit
serum +10% C’
1
75
100
100
150
200
200
150
200
270

aN44smcOmp85
without C’
75
75
75
50
75
75
75
50
50
50

Table 4: Bactericidal assay to evaluate complement-mediated killing of A. gonorrhoeae JSl
induced by aN445mcOmp85. Number of colonies counted on each plate is indicated.
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1
1
1
1
1
1
1
1
1
1

2
4
8
16
32
64
128
256
512
1024

aN44s*ncOmp85
+10% C’
0
0
0
0
0
0
0
0
4
14

Normal rabbit
serum +10% C’
0
0
0
0
0
2
4
8
17
16

aN44smcOmp85
without C’
50
100
100
80
100
100
80
40
22
75

Table 5: Bactericidal assay to evaluate complement-mediated killing of N. gonorrhoeae FA638
induced by aN445mcOmp85. Number of colonies counted on each plate is indicated.
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Figure 11. Western blot comparing reactivity of biotinylated gonococcal cells to that of
unlabeled gonococcal cells. Anti-N445mcOmp85 serum was used as the probe. Lane 1,
GIBCO Benchmark prestained molecular weight marker (MWM), expressed in kilodaltons;
lane 2, unlabeled N. gonorrhoeae MSI 1 surface proteins; lane 2, biotinylated N.
gonorrhoeae MSI 1 surface proteins.
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(Figure 12). These results suggest that biotm labeling whole cells severely hinders binding of
anti- N445mcOmp85.
3-6. Immunoprécipitation
Since biotin labeling was found to prevent binding of anti- N44smcOmp85 to whole cells, an
immunoprécipitation experiment was performed on unlabeled cells to assay surface exposure of
Omp85. Whole cells were incubated with anti-N44snicOmp85 serum for 1 hr, at which point the
cells were washed to eliminate unbound antibodies. The cells were then incubated with protein
A-sepharose beads for 1 hr, followed by addition of a mild lysis buffer to release antigenantibody complexes from the cell membrane. The beads were subsequently washed. Proteins
bound to the beads were visualized by solubilizing the beads in SDS-PAGE buffer, then
analyzing the solute via Western blot. Probing the blot with anti- N44smcOmp85 revealed a band
of ~85 kDa (Figure 13). The intensity of the ~85 kDa band increased when the same number of
cells were sonicated prior to immunoprécipitation. This was expected, since disrupting the
membrane would increase the number o f epitopes exposed. An -85 kDa protein was not detected
from the sepharose beads when whole cells were immunoprecipitated with either normal rabbit
serum or dPBS, indicating that the -85 kDa protein was immunoprecipitated specifically by antiN445mcOmp85 serum. The multiple bands that appeared below the 52.5 kDa molecular weight
marker resulted from protein A being solubalized off the sepharose beads, since protein Asepharose beads, on their own, produced the same banding pattern.
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Comparison of reactivities of
biotinylated- vs. unlabelled
gonococcal cells against various
rabbit antisera
□ Biotinylated
gonococcal
surface proteins
■ Unlabelled
gonococcal
surface proteins

Q 0.15

Rabbit antiserum

Figure 12. ELISA demonstrating reactivity of various rabbit antisera against biotinylatedand unlabeled N. gonorrhoeae MS 11 LOS A. Biotinylated cells are depicted with blue bars;
unlabeled cells are depicted with maroon bars. The following rabbit antisera were used to
assay reactivity: anti-N445mcOmp85; serum raised against the first 173 amino acids of
gonococcal Omp85 (anti-PM04); serum raised against amino acids 445-798 of
meningococcal Omp85 (2(.5)mcOmp85); and normal rabbit serum (NRS).
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Figure 13. Western blot to visualize results of immunoprécipitation assay on
gonococcal cells. Immunoprécipitation of gonococcal cells was performed using antiN445mcOmp85 antiserum and protein A-sepharose beads. Proteins subsequently bound
to the sepharose beads were visualized by solubilizing the sepharose beads, then
analyzed via Western blot, using anti-N445ntcOmp85 as a probe. Lane I, GIBCO
Benchmark prestained molecular weight marker (MWM), expressed in kilodaltons; lane
2, N. gonorrhoeae MSI 1 LOS A whole cells immunoprecipitated with antiN445mcOmp85; lane 3, N. gonorrhoeae MSI 1 LOS A that was sonicated prior to
immunoprécipitation with anti-N445nicOmp85; lane 4, N. gonorrhoeae MSI 1 LOS A
whole cells immunoprecipitated with normal rabbit serum (NRS); lane 5, N.
gonorrhoeae MSI I LOS A whole cells immunonrecioitated with PBS.
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Discussion
Pathogenic strains of Neisseria infect up to 250 million people worldwide annually (I3,5,28). N. meningitidis causes fulminant meningococcal sepsis and meningococcal meningitis,
which can have mortality rates of up to 80% and 5%, respectively (28). N. gonorrhoeae is the
causative agent of gonorrhea, a leading cause of urethritis, cervicitis, and pelvic inflammatory
disease in the United States. Early diagnosis of these diseases is often difficult; early symptoms
of meningococcal disease are very similar to those of viral and other bacterial diseases, while
detection of gonococcal infection is often hindered by the fact that up to 40% of infected men and
80% of infected women are asymptomatic for disease (23). Consequently, initiation of treatment
often does not occur until later during infection, resulting in decreased effectiveness of the
treatment and increased opportunity for unidentified carriers to spread the disease. Therefore,
disease prevention would most likely be the most effective cure. Unfortunately, the current
vaccine against N. meningitidis has limited effectiveness, and there is no vaccine available against
N. gonorrhoeae.
The hypothesis tested here was that rabbit antiserum generated against the first 445
amino acids o f a meningococcal 85 kilodalton (kDa) outer membrane protein (Omp85) promotes
specific complement-mediated killing o f N. meningitidis and N. gonorrhoeae. Omp85 is a
potential vaccine candidate since it is universally expressed by Neisseria, and its expression is
highly conserved (17). At the nucleic acid level, all strains within a species have identical
Omp85 (17). High interspecies homology exists at the amino acid level; meningococcal Omp85
is 95% identical and 98% similar to gonococcal Omp85 (17). In addition, Omp85 homologues in
Haemophilus influenzae and Pasteurella multocida were shown to induce protective immunity m
rats (8,16,18,26). Therefore, antibodies against Omp85 could potentially confer protection
against all strains of both N. meningitidis and N. gonorrhoeae. Evaluating the bactericidal
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activity o f serum against the first 445 amino acids of meningococcal Omp85 {anti-N445mcOmp85 )
was one approach to assay the vaccine potential of OmpSS. The N-terminal half of Omp85 was
focused upon here since it was previously shown that the entire molecule is difficult to express in
E. coli. In addition, systematic evaluation of different OmpSS fragments would allow for
pinpointing o f a putative bactericidal-eliciting epitope.
To purify adequate quantities of N4 4 5 mcOmp 8 S for rabbit immunization, DNA encoding
for N4 4 5 mcOmp 8 S, minus the signal sequence, was cloned into a hyperexpression vector. The
pTrcHis-TOPO® vector was used, which was designed to allow for insertion of PCR-amplified
products. This vector system included the following features: poly-histidine tag to allow for
affinity purification of the recombinant protein via a nickel column; trc promoter region for highlevel inducible expression in E. coli; lac operator binding site for the lac repressor; la c f gene
encoding for the lac repressor, which regulates the promoter; ampicillin resistance gene to allow
for selection o f transformants; origin derived from pBR322, a commonly used E. coli cloning
vector; and an Xpress^^ epitope for detection of the recombinant protein. Plasmid DNA from the
resulting transformants were analyzed using restriction enzymes AccI, BamHI, and EcoRI to
confirm correct orientation o f the insert. Expression of recombinant N44smcOmp85 was induced
with 1 mM IPTG, which prevents binding of the lac repressor to its corresponding operator.
Subsequent SDS-PAGE and CBB stain analysis revealed that expression levels were not as high
as expected. This may have been due to toxicity of the expressed recombinant protein to E. coli,
or a sub-optimal vector system. To address the latter possibility, N4 4 5 mcOmp8 S was subcloned
into pTrcHisB. The pTrcHisB vector differs from pTrcHis-TOPO® in that it lacks the TOPO
cloning site, and it has a ColEl-derived origin. Otherwise, pTrcHisB retains all other features of
pTrcHis-TOPO®. N4 4 5 mcOmp 8 S was inserted into the multiple cloning site of pTrcHisB using
E c o R I djaà 5 a m / / / (Figure I).

Following the transformation reaction, plasmid DNA from

resulting colonies was analyzed by PCR to confirm presence of the insert. Those clones that
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contained the insert were analyzed using restriction enzymes AccI, Hindlll, and M je/to confirm
correct orientation (see Figure 1 for map of restriction sites). Analysis of recombinant
N445mcOmp85 expression levels via SDS-PAGE and CBB staining showed increased protein
expression as compared to that achieved in pTrcHisTOPO (Figure 4). Therefore, the
pTrcHisTOPO vector was inefficient at expressing recombinant N44smcOmp85. Purification of
the fusion protein was performed via affinity chromatography using a nickel column. CBB
staining and Western blot analysis was used to confirm the identity of the purified protein as
N445mcOmp85 (Figures 6&7).
To generate anti-N445mcOmp85 serum, rabbits were immunized with purified
recombinant N44smcOmp85. Three months after primary immunization, anti-N445mcOmp85 serum
was at a titer of at least 1:32,000, as determined by Western blot strips containing whole cell
lysates o f N. gonorrhoeae MSI 1 LOS A. To ensure that the rabbits were not previously exposed
to Omp85 o f environmental strains, serum was collected prior to immunization (normal rabbit
serum, NRS). Western blot analysis showed that NRS did not react to either purified
recombinant N445mcGmp85 or Neisseria whole cell lysates (Figure 8 ). Thus, reactivity of antiN445mcOmp85 was a result of exposure to the immunogen, and not by exposure to environmental
Omp85-expressing strains. The reactivity of anti-N44smcOmp85 serum was further tested via
Western blot against the immunogen, N445mcOmp85-expressing clone, and various Neisseria
strains. Recombinant N445mcOmp85 has an expected molecular mass of 55 kDa; antiN445mcOmp85 detected a ~55 kDa protein in the lanes containing purified recombinant
N445mcOmp85 and the N445mcOmp85-expressing clone (Figure 10). This confirmed reactivity of
anti-N44snicGmp85 serum against the immunogen. Anti-N44smcGmp85 detected a ~85 kDa
protein in all lanes containing whole cell lysates of various Neisseria strains (Figure 10),
supporting previous observations that Gmp85 is universally expressed by Neisseria.
To evaluate anti- N44$mcGmp85 serum for its ability to specifically promote complementmediated killing of Neisseria, bactericidal assays were performed. Gne unencapsulated strain of
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N. meningitidis and four strains of N. gonorrhoeae were assayed for their susceptibility to
complement-mediated killing specifically promoted by anti- X44smc0mp85 rabbit serum (Tables
1-5). To quantify bactericidal activity, two-fold serial dilutions of the antiserum were performed
to allow for determination of a killing titer, which was defined as the reciprocal of the last serum
dilution that produced no bacterial growth. Various degrees of sensitivity to anti-N44imcOmp85
serum was observed among the strains tested. However, most strains that exhibited sensitivity to
anti-N445mcOmp85 serum were equally sensitive to NRS, indicating that killing was a result of
serum components other than anti- N44snicOmp85 antibodies. N. meningitidis 8543 was unable to
grow in any serum dilution containing 10% human complement. This agreed with previous work,
which showed that unencapsulated meningococcal strains are much more sensitive to normal
human serum (NHS) as compared to encapsulated strains; all unencapsulated, non-sialylated
strains o f N. meningitidis showed some degree of serum sensitivity to 10% NHS (22). Therefore,
to determine killing titer of anti-N445mcOmp85 rabbit serum against N. meningitidis 8543,
complement concentration was reduced to 5%. This resulted in a killing titer of approximately 4
(Table 1). However, NRS also produced a killing titer of approximately 4, indicating that killing
observed with this meningococcal strain was not due to anti- N445mcOmp85 antibodies.
N. gonorrhoeae MS 11 LOS A was resistant to all dilutions of anti- N445mcOmp85 serum
and NRS.
N. gonorrhoeae FA19 was also resistant to all dilutions of anti-N445mcOmp85 and NRS.
Resistance to NRS killing observed here agrees with previous work by Pettit et al. (20), which
demonstrated that N. gonorrhoeae FA19 exhibited >50% survival in 25% pooled NHS. This
particular gonococcal strain was isolated from a patient with disseminated gonococcal infection
(DGI). Since DGI strains tend to be more serum resistant as compared to strains from
uncomplicated gonococcal infections (20), NRS resistance exhibited by N. gonorrhoeae FA 19
agreed with previous results.
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N. gonorrhoeae JSl was sensitive to killing by anti-N445mcOmp85, producing a killing
titer o f approximately 2. However, NRS also produced a killing titer of approximately 2,
suggesting that the killing induced by anti-N44snicOmp85 was non-specific. Pettit et al. (20)
found N. gonorrhoeae JSl to be resistant to killing by 25% pooled normal serum. This
discrepancy in sensitivities to normal serum may be due to differing serum components between
NRS and NHS. N. gonorrhoeae JSl was isolated from a patient with uncomplicated gonococcal
infection; since such strains are often sensitive to serum killing (20), the observation that JSl is
sensitive to NRS is likely not anomalous.
TV. gonorrhoeae FA638 was sensitive to killing by anti-N445mcOmp85, producing a killing
titer o f 512. This was approximately twice the killing titer produced by NRS, suggesting that
antibodies against N44smcOmp85 promoted some degree of complement-mediated killing against
this strain. TV. gonorrhoeae FA638 was previously shown to have truncated lipooligosaccharide
(LOS) (20). Thus, it is possible that this strain’s sensitivity to anti-\44smcOmp85-specific killing
was due to increased surface exposure o f Omp85 epitopes. It may also be possible that TV.
gonorrhoeae FA638 expressed more Omp85 than other strains, although such differences in outer
membrane protein expression levels between strains have never been addressed.
The strains tested here exhibited varying degrees of sensitivity to NRS killing. Several
factors contributing to serum sensitivity in Neisseria have been previously described.
Cytidinemonophospho-N-acetylneuramic acid (CMP-NANA), the nucleotide sugar of sialic acid,
confers serum resistance upon binding to LOS (22). Both meningococci and gonococci are
capable o f being sialylated; however, only meningococci are capable of endogenous LOS
sialylation (22). Human secretions serve as the source of sialic acid for most resistant gonococcal
strains; therefore serum resistance is often lost after repeated subcultures ( 2 2 ). Sialylated
gonococci resist serum killing by exhibiting increased binding to factor H (22). which regulates
the complement cascade by inactivating surface-bound C3b. Binding of factor H to surfacebound C3b was demonstrated using non-sialylated gonococci, which bound factor H only if the
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cells were previously incubated in NHS; non-sialylated gonococci that were previously incubated
in heat-inactivated serum did not bind factor H (22). Since heating serum causes the inactivation
of complement proteins, these observations indicated that factor H binds non-sialylated cells only
if they were previously coated with C3b.
Porin (For) is another factor that contributes to serum resistance. Gonococci express one
o f two porin isoforms. For A or For B (22). Strains that express For A are often associated with
DGI, which in turn are associated with serum resistance (22). Gonococci that express For B are
more closely associated with local urogenital disease (2 2 ), and tend to be more serum sensitive.
Therefore, For A expression is often indicative of a serum resistant phenotype. Serum resistance
in For A-expressing strains may be due to the fact that factor H preferentially binds For A over
For B (22). As a result. For A strains have less surface-bound C3b, which is inactivated by factor
H. The role of For A-factor H binding in conferring serum resistance was studied using
monoclonal antibodies against the fifth loop of For A (a-sLFor A), which serves as the binding
site for factor H. Serum resistant strains that were incubated with a-stPor A antibodies were
subsequently rendered sensitive to NHS (22). Thus, binding of factor H to For A plays a role in
conferring serum resistance in gonococci.
Serum resistance associated with For A-expressing strains may also be partially attributed
to the fact that C4b-binding protein (C4bp) preferentially binds For A over For B (22). C4bp is a
fluid-phase regulator of the classical pathway, and is involved in mediating inactivation of C4b.
Since C4b is required for the formation of C3 convertase in the classical pathway, C4b
inactivation results in serum resistance by preventing accumulation of C3b.
In meningococci, encapsulation and sialylation are the two main factors contributing to
serum resistance and virulence. It was previously shown that strains isolated from patients with
invasive meningococcal disease possess both a capsule and sialylated LOS (22). In addition, only
strains possessing both a capsule and sialylated LOS were capable of causing bacteremia in
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infanat rats (22). All encapsulated strains exhibited at least 20% survival in 10% NHS (22), while
non-encapsulated, non-sialylated strains showed some degree of sensitivity to the same
concentration of NHS (22). Encapsulation and sialylation have an additive effect on conferring
serum resistance, since encapsulated, sialylated strains were more serum resistant than
encapsulated, non-sialylated strains (22). Furthermore, exogenous addition of CMP-NANA to
encapsulated strains increased serum resistance in encapsulated, non-sialylated strains ( 2 2 ).
Encapsulation likely confers serum resistance by masking outer membrane binding sites for C4
and C5b (22). 0 4 participates in the classical pathway by serving as the precursor to C4b, which
is one of the components of the 03 convertase. 05b binds cell surfaces, and provides a
foundation for the formation of membrane attack complex (MAO). Thus, serum resistance in
meningococci results primary from thwarting MAC formation on the cell surface. This is in
contrast to gonococci, which resist serum primarily by the prevention of 03b deposition on the
cell surface.
Previous studies showed that bactericidal activity of antibodies against major Neisserial
surface antigens is affected by sialylation (7). Antibodies against LOS and Por are less
bactericidal to sialylated cells, as compared to non-sialylated cells (7). Therefore, sialylation may
also prevent bactericidal activity of antibodies against Omp85.
In this project, 4 out o f the 5 Neisseria strains assayed were not sensitive to com plem entm ediated killing that was specifically promoted by anti-N445nicOmp85 rabbit serum. One strain
show ed only slight sensitivity to anti-N44smcOmp85-mediated com plem ent killing; there was only
an approxim ately tw o-fold difference in killing titer betw een anti-N445mcOmp85 and NRS
(Table). The inability o f anti-N445mcOmp85 rabbit serum to generate a strong, specific
bactericidal response may be attributed to any o f the factors, described above, that confer serum
resistance upon Neisseria. It is also likely that the paucity o f Omp85 m olecules on the cell
surface may be a contributing factor preventing anti-N44;mcOmp85 serum from exhibiting specific
bactericidal activity. Quantifiable CBB staining o f Neisseria w hole cell lysates indicated that
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Omp85 comprises only a minute percentage of total outer membrane proteins. This would hinder
anti-N445mcOmp85-mediated complement killing by the classical pathway, since it drastically
decreases the chance that two Omp85 molecules would be in close enough proximity to allow for
cross-linking by IgG. The pentameric nature of IgM would allow it to cross-link a single Omp85
molecule, and thus potentially initiate the classical pathway; however, because the high titer
serum used in these bactericidal assays was collected after several months of immunization, the
vast majority o f immunoglobulins had already experienced a class-switch to the IgG isotype.
Thus, it might be difficult for Omp85 to elicit bactericidal antibodies. Previous work showed that
Neisseria are not susceptible to antibody-independent complement killing via the alternative
pathway (22). This may explain the complete inability of anti-N445mcOmp85 rabbit serum to
produce killing in some of the strains tested here.
To discount the possibility that anti-N44smcOmp85 serum did not exhibit bactericidal
activity due to lack of Omp85 surface exposure, immunoprécipitation assays were performed on
biotinylated gonococcal whole cells. Cells were biotinylated prior to immunoprécipitation for the
purpose o f amplifying any potential signal, by treatment with streptavidin-peroxidase conjugate,
that may result from immunoprécipitation by anti-N445mcOmp85 serum. Signal amplification
was desired since Omp85 molecules appeared to be sparse in the outer membrane; thus, antiN445mcOmp85 antibodies likely would not immunoprecipitate sufficient quantities of Omp85
molecules to allow for detection without signal amplification. Biotinylated whole cells were
treated with a mild lysis buffer to release antigens. The lysed cells were then incubated with
protein A-sepharose beads and anti- N44smcOmp85 serum to precipitate out any labeled Omp85
molecules. The sepharose beads were subsequently washed. To determine if the beads had
bound any biotin-labeled Omp85 molecules, the beads were solubalized, separated on SDSPAGE gel, and then transferred to a PVDF membrane. To detect the presence of any biotinlabeled proteins, the membrane was incubated with streptavidin-peroxidase conjugate, then
developed on autoradiography film. This procedure failed to detect any 85 kDa proteins, which
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indicated that anti- N44smcOmp85 serum was unable to bind epitopes on biotin-labelled whole
cells. This suggested that the epitope recognized by anti- N445mcOmp85 was not surface exposed;
alternatively, the epitope may have been surface exposed, but steric hindrance caused by biotin
labeling may have prevented binding of anti- N44snicOmp85 antibodies. To test the latter
possibility, biotinylated- and unlabeled gonococci were analyzed by Western blotting, using antiN445mcOmp85 serum as a probe. No bands were detected in the lane containing biotinylated
cells, while an 85 kDa band was detected in the lane containing unlabeled cells (Figure 11).
Similar results were observed via ELISA: biotinylated cells produced a diminished signal, as
compared to unlabeled cells (Figure 12). Biotinylation also hindered binding of antibodies
against the first 173 amino acids of gonococcal Omp85 (anti-PM04) and antibodies against
amino acids 445-798 of meningococcal Omp85 (anti-2(.5)mcOmp85) (Figure 12). Collectively,
these results suggested that biotinylation sterically hindered antibody binding to the majority of
Omp85 epitopes. This indirectly pointed to the surface-exposed nature of Omp85. Because
biotinylation exclusively labeled surface-exposed proteins of whole cells, and biotinylation
hindered antibody binding to Omp85, it may be deduced that Omp85 is a surface-exposed
molecule.
To obtain more direct evidence of Omp85 surface exposure, an immunoprécipitation
experiment was performed on unlabeled gonococcal whole cells. Whole cells were incubated
with anti-N44smcOmp85 serum, after which unbound antibodies were washed away. The cells
were then incubated with protein A-sepharose beads, followed by treatment with a mild lysis
buffer to release antigens. The beads were then washed. To determine if the beads had bound
any Omp85 molecules, the beads were solubalized, then analyzed by Western blot, using antiN445mcOmp85 serum as a probe. This resulted in detection of an -85 kDa protein (Figure 13). A
much more intense 85 kDa band was detected when the cells were sonicated prior to
immunoprécipitation. This indicated that many Omp85 surface epitopes are inaecessible to
antibodies due to a transmembrane or intracellular location, or due to masking by LOS. The
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increased signal caused by sonication also suggests that immunoprécipitation of Omp85 from
whole cells was due to surface exposure of Omp85, rather than release of Omp85 from autolyzed
cells.
Taken together, these results indicated that the Omp85 epitope recognized by antiN445mcOmp85 serum is surface-exposed. This agrees with previous observations suggesting that
Omp85 is an outer membrane protein. These observations include the presence of a signal
peptide (29) and a C-terminal phenylalanine (25), a 10 amino acid C-terminal motif indicative of
outer membrane proteins (25), and reactivity of anti-Omp85 antibodies against isolated
gonococcal outer membranes (Quick and Judd, see Figure 14). Therefore, anti- N445mcOmp85
serum was not prevented from exhibiting strong bactericidal activity due to lack of Omp85
surface exposure. More likely, other factors contributed to the lack of bactericidal activity of
anti-N44smcOmp85. These include the scarcity of Omp85 in the outer membrane, which may
have prevented antigen cross-linking by antibody, and therefore thwarted initiation of the
complement cascade via the classical pathway. It is also possible that the nature of the
N44smcOmp85 antigen and the method used to immunize the rabbit prevented a predominant IgG3
response, which is the subclass of IgG most effective at activating complement (10). It was
previously shown that variations in LOS phenotype altered surface-exposure of other Neisseria
outer membrane proteins (14). Therefore, it is possible that the lack of anti-N445mcOmp85
bactericidal activity was due to an outer membrane protein-masking LOS phenotype expressed by
the strains tested.
Despite the lack of bactencidal activity exhibited by anti- N445mcOmp85 serum, Omp85 is
still a promising vaccine candidate. Since the antiserum studied in this project was raised against
the N-terminal half of Omp85, it may be possible that epitopes located in the C-terminal half
elicit bactericidal antibodies. Since the function of Omp85 has yet to be determined, it is also
possible that antibodies against Omp85 may hinder an essential function or block cell adhesion.
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anti-Omp85 serum

Figure 14 (Courtesy of Quick and Judd). Cellular location of Omp85 by Western blot
analysis. Lysates of whole cels (WC), cytoplasm, isolated inner membranes (IM), periplasm
and isolated outer membranes (OM) of Neisseria gonorrhoeae MSI 1 LOS A separated in a
12.5% SDS-PAGE gel, blotted and probed with anti serum raised to the first 178 amino acids
o f Omp85 (antl-Omp85 serum). The Omp85 is identified. Molecular mass markers (MW),
expressed in kilodaltons (k), were GIBCO Benchmark prestained markers. These results
indicated that Omp85 was found only in whole cells and isolated outer membranes,
confirming that Omp85 is an outer membrane protein.
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The vaccine potential of Omp85 is further implicated by its universal and conservative expression
in all pathogenic Neiseria.

Furthermore, Omp85 homologues m Haemophilus influenzae and

Pasteurella multocida were shown to induce protective immunity in rats (8,16,18,26). Thus,
further studies examining the vaccine potential of Omp85 are warranted.
In summary, anti-N44snicOmp85 rabbit serum did not exhibit specific bactericidal activity
against 4 o f 5 Neisseria strains. N. gonorrhoeae FA638 was slightly susceptible to antiN4 4 5 mcOmp 8 5-mediated complement killing; the killing titer produced by anti-N445mcOmp85
against FA638 was approximately twice that produced by NRS. The slight sensitivity of FA638
to anti-N445mcOmp85 killing may be attributed to truncated LOS (20), which may allow for
greater surface exposure of the Omp85 molecule. Alternatively, this strain may express more
Omp85 as compared to other Neisseria strains. To determine if bactericidal activity of antiN445mcOmp85 was hampered due to lack of surface exposure of the corresponding epitope,
immunoprécipitation assays were performed on gonococcal whole cells using anti- N445mcOmp85
serum. Results from these experiments indicated that the epitope recognized by antiN44smcOmp85 was indeed surface-exposed. Therefore, the lack of specific bactencidal activity
exhibited by anti- N44smcOmp85 was more likely a consequence of other factors. These include
the low abundance of Omp85 molecules on the outer membrane, which would decrease the
likelihood o f antibody cross-linking to two adjacent antigens, thus preventing initiation of the
classical complement pathway. It is also possible that the nature of the N44smcOmp85 antigen and
the method o f immunization prevented a sufficient IgG3 response, thus hindering complement
activation. LOS phenotype of the test strains may have also played a role, since previous work
showed that variations in LOS may mask surface exposure of other Neisseria outer membrane
proteins (14).
A lthough anti-N44smcOmp85 serum lacked bactericidal activity, Omp85 is still an
attractive vaccine candidate. U nlike m ost previous Neisseria outer membrane protein vaccine
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candidates, Omp85 is universally and conservatively expressed by Neisseria. Moreover, Omp85
homologues in Haemophilus influenzae and Pasteurella multocida were shown to induce
protective immunity in rats (8,16,18,26); therefore, antibody binding to Omp85 may disrupt some
essential function, or may prevent cell adhesion. In addition, since the anti serum used in this
project was raised against the N-terminal half of Omp85, it may be possible that epitopes in the
C-terminal half of the molecule may elicit generation of bactericidal antibodies. Thus, further
studies examining the function of Omp85 and the ability of anti-Omp85 antibodies to hinder
pathogenicity of Neisseria warranted.
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